Full data chronic kidney disease trial efficacy
Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
Search
EFPIA Disclosure Code
eRfx – Supplier Training Deck
Supplier Training Deck - Invoice
Supplier Light Account Quick Guide
FAQ1_Supplier_Training_Deck_v3.pdf
Keep water clean
Human beings can’t survive without water. Further, the safe production of medicines depends on clean drinking water.
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Inauguration of new integrated Asian Veterinary R&D Center in China
Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
European Commission decision for Pradaxa® in children with VTE
Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age
Positive-CHMP-opinion-for-dabigatran-in-children
Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children
Dogs at work in Milan offices
Dogs at work is a pilot project that allows pet-lover to bring their dogs to the office and enjoy the benefits they bring to their daily work life.
Our culture
Our culture reflects who we are and is reflected in Our FOCUS and strong belief in Diversity, Equity and Inclusion as well as Sustainable Development.
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Supporting Fundappas
Supporting Fundappas in Uruguay to improve quality of life of dogs and people.
NEJM-IL-36-Phase-1-GPP-data
Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Phase 1 start for novel triple agonist obesity treatment
Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment
PRRS Research Award 2022
Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
Stroke symptoms
The Angels initiative, stroke symptoms, giving life a chance, optimizing stroke care
Boehringer Ingelheim appointment to Board Managing Directors
Boehringer Ingelheim announces appointments to Board of Managing Directors
Boehringer Ingelheim Venture Fund invests precision antimicrobials
Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials